Zonisamide

Generic Name: Zonisamide

Brand Names: Zonegran, Zonisade, Zonisamide Mylan

Drug Type: Small Molecule

Chemical Formula: C_₈H_₈N_₂O_₃S

CAS Number: 68291-97-4

Unique Ingredient Identifier: 459384H98V

Background: Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory...

Indication: Zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Zonisamide oral suspension is indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years of age and older.

Associated Conditions: Partial-Onset Seizures

Associated Therapies: -

Clinical Trials

Zonisamide in the Treatment of Essential Tremor

Not Applicable

Terminated

Conditions: Essential Tremor

Interventions: Drug: Zonisamide

First Posted Date: 2008-02-15

Last Posted Date: 2014-07-17

Lead Sponsor: Loma Linda University

Target Recruit Count: 9

Registration Number: NCT00616343

Zonisamide vs. Placebo in the Treatment of Alcohol Dependence

Phase 4

Completed

Conditions: Alcoholism
Alcohol Abuse
Alcohol Dependence

Interventions: Drug: Placebo
Drug: zonisamide

First Posted Date: 2008-01-16

Last Posted Date: 2010-10-15

Lead Sponsor: UConn Health

Target Recruit Count: 40

Registration Number: NCT00595556

Locations: 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States

Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)

Phase 3

Completed

Conditions: Epilepsy; Paediatric Partial Onset Seizures

Interventions: Drug: Placebo
Drug: Zonisamide

First Posted Date: 2007-12-03

Last Posted Date: 2013-05-13

Lead Sponsor: Eisai Inc.

Target Recruit Count: 207

Registration Number: NCT00566254

A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy

Phase 3

Completed

Conditions: Epilepsy

Interventions: Drug: Carbamazepine
Drug: Zonisamide

First Posted Date: 2007-05-23

Last Posted Date: 2015-12-24

Lead Sponsor: Eisai Inc.

Target Recruit Count: 583

Registration Number: NCT00477295

The Effects of Zonisamide on Alcohol Dependence

Phase 2

Completed

Conditions: Alcoholism

Interventions: Drug: Zonisamide

First Posted Date: 2006-12-04

Last Posted Date: 2010-05-11

Lead Sponsor: Boston University

Target Recruit Count: 16

Registration Number: NCT00406692

Locations: 🇺🇸
Boston University School of Medicine, Boston, Massachusetts, United States

Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

Phase 3

Completed

Conditions: Schizophrenia
Schizoaffective Disorders

Interventions: Drug: olanzapine
Behavioral: Wellness education
Drug: amantadine
Drug: metformin
Drug: zonisamide

First Posted Date: 2006-11-22

Last Posted Date: 2009-10-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 199

Registration Number: NCT00401973

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation

Alcohol Self Administration Laboratory

Not Applicable

Completed

Conditions: Alcoholism

Interventions: Drug: zonisamide
Drug: Placebo

First Posted Date: 2006-11-14

Last Posted Date: 2017-07-14

Lead Sponsor: Boston University

Target Recruit Count: 10

Registration Number: NCT00398918

Locations: 🇺🇸
Boston University Medical Campus, Boston, Massachusetts, United States

A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

Phase 3

Completed

Conditions: Weight Gain

Interventions: Drug: Zonisamide
Drug: olanzapine
Drug: Sugar Pill (placebo)

First Posted Date: 2006-08-15

Last Posted Date: 2012-04-13

Lead Sponsor: Lindner Center of HOPE

Target Recruit Count: 42

Registration Number: NCT00363376

Locations: 🇺🇸
The Lindner Center of HOPE, Mason, Ohio, United States

Evaluating the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures

Phase 3

Completed

Conditions: Partial Seizures

Interventions: Drug: Placebo
Drug: Zonisamide

First Posted Date: 2006-05-18

Last Posted Date: 2014-08-15

Lead Sponsor: Eisai Inc.

Target Recruit Count: 240

Registration Number: NCT00327717

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳
Peking Union Hospital, Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

and more 5 locations

A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures

Phase 3

Completed

Conditions: Epilepsy

Interventions: Drug: Zonisamide
Drug: Lamotrigine

First Posted Date: 2006-02-16

Last Posted Date: 2013-05-20

Lead Sponsor: Eisai Inc.

Target Recruit Count: 64

Registration Number: NCT00292461

Locations: 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan, China
🇨🇳
Chang-Gung Memorial Hospital (CGMH), Taipei, Taiwan, China
🇨🇳
Changhua Christian Hospital, Changhua, Taiwan, China

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy